Internal Medicine, Hematology & Oncology · Encinitas, CA
NPI
1003888074
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
326 Santa Fe Dr Ste 105
Encinitas, CA, 92024
Phone (760) 452-3340
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
331,833 services
Medicare patients, 2024
680
Average age 76
Drug cost, 2024
$5.4M
696 prescriptions
Company payments, 2025
$3,924
From 47 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alberto Bessudo was code Q5125 (injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram), 68,760 times for 17 patients. In total Alberto Bessudo billed 331,833 services in 164 codes, and Medicare paid $4.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-19.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 68,760 | 17 | $0.39 | $27K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 65,900 | 65 | $2.31 | $152K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,000 | 23 | $0.88 | $21K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,190 | 12 | $0.06 | $1,213 |
| J0897 Injection, denosumab, 1 mg | Office | 16,380 | 73 | $20.56 | $337K |
| J0185 Injection, aprepitant, 1 mg | Office | 15,600 | 33 | $1.34 | $21K |
| J9299 Injection, nivolumab, 1 mg | Office | 13,400 | 13 | $24.69 | $331K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 6,400 | 23 | $4.39 | $28K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,040 | 65 | $0.09 | $273 |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 3,020 | 13 | $52.48 | $158K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,200 | 21 | $15.75 | $35K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,068 | 13 | $31.89 | $66K |
| Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Office | 1,572 | 37 | $258.03 | $406K |
| 85025 Blood Count | Office | 1,558 | 247 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | Office | 1,368 | 259 | $8.65 | $12K |
By year: 2022 $4.1M for 403,641 services; 2023 $3.8M for 256,865 services; 2024 $4.2M for 331,833 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,558 | 247 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | 1,368 | 259 | $8.65 | $12K |
| 81002 Clinical Chemistry | 70 | 25 | $3.41 | $239 |
| 80053 Clinical Chemistry | 44 | 38 | $10.35 | $455 |
Medicare prescription drug claims, 2024
In 2024, the drug Alberto Bessudo prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 63 prescriptions and refills. In total Alberto Bessudo wrote 696 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 63 | 63 | Under 11 | $1.1M |
| Jakafi Ruxolitinib Phosphate | 60 | 61 | Under 11 | $983K |
| Eliquis Apixaban | 47 | 50 | 13 | $26K |
| Xtandi Enzalutamide | 36 | 36 | Under 11 | $501K |
| Hydroxyurea Generic | 28 | 76 | Under 11 | $579 |
| Pomalyst Pomalidomide | 28 | 28 | Under 11 | $628K |
| Ondansetron Odt Ondansetron | 27 | 27 | 19 | $553 |
| Dexamethasone Generic | 26 | 30 | 15 | $454 |
| Lenalidomide Generic | 25 | 25 | Under 11 | $376K |
| Prochlorperazine Maleate Generic | 23 | 23 | 18 | $228 |
| Bicalutamide Generic | 21 | 47 | Under 11 | $572 |
| Anagrelide Hcl Generic | 20 | 39 | Under 11 | $12K |
| Venclexta Venetoclax | 20 | 20 | Under 11 | $186K |
| Revlimid Lenalidomide | 19 | 19 | Under 11 | $326K |
| Gabapentin Generic | 17 | 18 | Under 11 | $530 |
Brand drugs: 365 claims; generic drugs: 331 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alberto Bessudo $3,924 ($3,924 in general payments such as food, travel and fees) from 47 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $440.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $440 |
| Genzyme Corporation SNY | 7 | $392 |
| Abbvie Inc. ABBV | 16 | $300 |
| Pfizer Inc. PFE | 13 | $291 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $247 |
| Exelixis Inc. EXEL | 7 | $201 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $186 |
| Alexion Pharmaceuticals, Inc. AZN | 5 | $163 |
| Merck Sharp & Dohme LLC MRK | 5 | $131 |
| Eisai Inc. 4523.T | 5 | $127 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.